UMIN ID: UMIN000000971
Registered date:07/01/2008
Clinical study of intratumoral dendritic cells(DC) injection after radiofrequency ablation(RFA) therapy for the treatment of hepatitis C virus-related hepatocellular carcinoma(HCC) patients
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Hepatocellular carcinoma |
| Date of first enrollment | 2008/02/01 |
| Target sample size | 10 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Intratumoral dendritic cells injection Radiofrequency ablation therapy |
Outcome(s)
| Primary Outcome | Safety |
|---|---|
| Secondary Outcome | Immunological responses, Clinical responses |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Patients who have: - Interstitial pneumonia, pulmonary fibrosis, or drug-induced pneumonia , or predisposition to them; - Continuous systemic administration of steroids; - Active autoimmune diseases or predisposition to them; - Other cancers; - Uncontrolled infection |
Related Information
| Primary Sponsor | Tokyo Medical University Hospital |
|---|---|
| Secondary Sponsor | Graduate School of Medicine, The University of Tokyo Seta Clinic Shin-Yokohama |
| Source(s) of Monetary Support | Ministry of Education, Culture, Sports, Science and Technology,Medinet Co.,Ltd |
| Secondary ID(s) |
Contact
| public contact | |
| Name | |
| Address | 6-7-1, Nishi-Shinjyuku, Shinjyuku-Ku, Tokyo, Japan Japan |
| Telephone | |
| Affiliation | Tokyo Medical University Department of Gastroenterology and Hepatology |
| scientific contact | |
| Name | Fuminori Moriyasu/Kazuhiro Kakimi |
| Address | 6-7-1, Nishi-Shinjyuku, Shinjyuku-Ku, Tokyo, Japan/7-3-1, Hongo, Bunkyo-Ku, Tokyo, Japan Japan |
| Telephone | |
| Affiliation | Tokyo Medical University/The University of Tokyo Department of Gastroenterology and Hepatology/Department of Immunotherapeutics (Medinet) |